Centessa Pharmaceuticals plc (CNTA)
NASDAQ: CNTA · Real-Time Price · USD
26.20
-0.31 (-1.17%)
At close: Mar 3, 2026, 4:00 PM EST
26.24
+0.04 (0.15%)
Pre-market: Mar 4, 2026, 7:25 AM EST
Centessa Pharmaceuticals Revenue
Centessa Pharmaceuticals had revenue of $15.00M in the twelve months ending September 30, 2025, up 118.88% year-over-year.
Revenue (ttm)
$15.00M
Revenue Growth
+118.88%
P/S Ratio
255.15
Revenue / Employee
$131,579
Employees
114
Market Cap
3.83B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 6.85M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ACADIA Pharmaceuticals | 1.07B |
| Corcept Therapeutics | 761.41M |
| TG Therapeutics | 616.29M |
| ADMA Biologics | 510.17M |
| Ligand Pharmaceuticals | 268.09M |
| NewAmsterdam Pharma Company | 22.50M |
| Crinetics Pharmaceuticals | 7.70M |
| Xenon Pharmaceuticals | 7.50M |
CNTA News
- 20 days ago - Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals - GlobeNewsWire
- 4 weeks ago - Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting - GlobeNewsWire
- 7 weeks ago - Nxera Pharma to Receive US$3.6 Million in Milestone Payment Pursuant to Research Collaboration with Centessa - GlobeNewsWire
- 2 months ago - Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications - GlobeNewsWire
- 4 months ago - Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares - GlobeNewsWire
- 4 months ago - Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares - GlobeNewsWire
- 4 months ago - Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program - GlobeNewsWire